Grace Therapeutics
GRCE
20 hedge funds and large institutions have $11.3M invested in Grace Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
24% more capital invested
Capital invested by funds: $9.17M → $11.3M (+$2.18M)
18% more funds holding
Funds holding: 17 → 20 (+3)
1.73% less ownership
Funds ownership: 29.33% → 27.6% (-1.7%)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$409K |
| 2 |
MFA
Millington Financial Advisors
Naperville,
Illinois
|
+$53.2K |
| 3 |
PWM
Palumbo Wealth Management
Great Neck,
New York
|
+$6.74K |
| 4 |
SPIA
Steward Partners Investment Advisory
New York
|
+$109 |
| 5 |
Jones Financial Companies
Des Peres,
Missouri
|
+$77 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$516K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$444K |
| 3 |
Renaissance Technologies
New York
|
-$38.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$10.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.53K |
GRCE Hedge Fund Activity: Q2 2025 in Review
20 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q2 2025, worth a combined $11.3M — up 24% from $9.17M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GRCE positions and 1 closed out — a net gain of 3 holders — while 2 added to existing stakes and 7 trimmed.
The largest buyer was Vanguard Group, adding an estimated $409K. The largest seller was AIGH Capital Management, cutting an estimated $516K.
- 20 institutional investors held Grace Therapeutics (GRCE) as of Q2 2025, up from 17 in Q1 2025.
- Funds reported $11.3M of Grace Therapeutics stock for Q2 2025, up 24% quarter-over-quarter.
- 4 funds opened new Grace Therapeutics positions in Q2 2025 and 1 closed out, a net change of +3 holders.
- The largest Grace Therapeutics buyer in Q2 2025 was Vanguard Group, an estimated $409K added.
- The largest Grace Therapeutics seller in Q2 2025 was AIGH Capital Management, an estimated $516K sold.
Based on aggregated 13F filings for Q2 2025.